Denali Therapeutics Inc. (DNLI)

NASDAQ

$18.67

$-0.26

(-1.37%)

After-Hours

Denali Therapeutics Inc. (DNLI) Live Price Chart

Last updated: ⁦2026-10-21 22:29:20⁩. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.

Summary

Denali Therapeutics Inc. (DNLI) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $18.67, with a market capitalization of $2.88B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.75 to $27.30. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$2.88B
Open	$18.93
Day's High	$93.94
Day's Low	$10.57
Previous Close	$18.93
Volume	1.17M
Average Volume	1.60M
P/E Ratio	--
52-Week High	$27.30
52-Week Low	$13.75
Dividend Yield	--
Earnings Date	--

Denali Therapeutics Inc. (DNLI) After-Hours Stock Price

Denali Therapeutics Inc. (DNLI) is trading at $18.94 in after-hours trading as of 2026-10-21 21:40:00, up 0.07% ($0.01) from the regular-session close of $18.93.

After-hours trading shows how investors are pricing DNLI after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.

Denali Therapeutics Inc. (DNLI) 7-Day Stock Price Change

Over the past seven days, Denali Therapeutics Inc. (DNLI) moved from $18.95 to $18.67, representing a decline of 1.47% ($0.28).

The stock traded between $17.33 and $19.62 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.

The average daily volume was 2.04 million shares, up versus the previous seven-day period, indicating higher trading activity.

DNLI 52-Week Price Position

Position in Range: 36.3%

52W Low$13.75

52W High$27.30

DNLI is currently trading at $18.67, placing it 36.3% of the way from its 52-week low of $13.75 to its 52-week high of $27.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Denali Therapeutics Inc. (DNLI)?

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Denali Therapeutics Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	507
Exchange	NASDAQ
Company Website	https://www.denalitherapeutics.com

How to Buy Denali Therapeutics Inc. (DNLI) Stock on MEXC

Eligible investors can buy real shares of Denali Therapeutics Inc. (DNLI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for DNLI and Place Your Order

Open the RealStocks trading page and search for DNLI. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Denali Therapeutics Inc. (DNLI) stock price today?

Denali Therapeutics Inc. (DNLI) is currently trading at $ 18.67, down 1.36% ($0.26) from the previous close of $ 18.93. Intraday prices update in real time during regular trading hours.

2.Is DNLI stock going up or down today?

As of 2026-10-21 21:40:00, DNLI is trading at $ 18.67, down 1.36% ($0.26) from its previous close of $ 18.93. The stock has traded between $ 10.57 and $ 93.94 during today’s regular session. Past price movements do not guarantee future results.

3.What is DNLI pre-market price?

As of 2026-10-21 21:40:00, DNLI is trading at $ 18.96 in pre-market trading, up 0.13% ($0.02) from the previous close of $ 18.93. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is DNLI after-hours price?

As of 2026-10-21 21:40:00, DNLI is trading at $ 18.94 in after-hours trading, up 0.07% ($0.01) from the regular-session close of $ 18.93. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is DNLI stock trading now?

DNLI trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does DNLI sit relative to its 52-week high and low?

Over the past 52 weeks, DNLI has traded between a low of $ 13.75 and a high of $ 27.30. At $ 18.67, the stock is positioned 36.3% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Denali Therapeutics Inc. in?

Denali Therapeutics Inc. (DNLI) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Denali Therapeutics Inc.'s market capitalization and where is it listed?

Denali Therapeutics Inc. is listed on the NASDAQ exchange with a market capitalization of $ 2.88B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is DNLI valued in terms of P/E ratio and EPS?

DNLI trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -3.21. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Denali Therapeutics Inc. pay a dividend?

Denali Therapeutics Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.